DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Geodon" report has been added to ResearchAndMarkets.com's offering.
Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. It subsequently gained approval for bipolar disorder indications in the US and EU in August 2004 and October 2005, respectively.
In March 2011, Meiji Seika Kaisha acquired exclusive rights to develop and commercialize ziprasidone in Japan, with RaQualia Pharma being eligible for developmental milestones and royalties on commercial sales. RaQualia Pharma announced in March 2015 that it had initiated a Phase III trial in Japan studying Geodon for the treatment of schizophrenia. The author believes that the companies are focusing on development for schizophrenia first before pursuing bipolar disorder.
Key Topics Covered
- Drug Overview
- Product Profiles
- Geodon: Bipolar Disorder
List of Figures
Figure 1: Geodon for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Geodon in bipolar disorder
Figure 3: Drug assessment summary for Geodon in bipolar disorder
List of Tables
Table 1: Geodon bipolar disorder indication approvals
Table 2: Geodon drug profile
Table 3: Overview of key clinical trial data for Geodon in bipolar disorder
Table 4: Treatment-emergent adverse reactions in =5% of Geodon-treated adult patients with bipolar mania in double-blind, placebo-controlled trials
Table 5: Geodon ongoing late-phase clinical trials as a therapy in children and adolescents with bipolar I disorder
Table 6: Overview of key clinical trial data for Geodon in bipolar depression
For more information about this report visit https://www.researchandmarkets.com/research/jhf3bf/geodon_pfizer?w=4
